Early Identification of Pulmonary Coccidioidomycosis


About this study

The purpose of this study is to identify, recruit, and enroll patients with community-acquired pneumonia (CAP) to collect their blood, sputum, urine, and a nasopharyngeal swab for specimen storage. The study also aims to develop a biomarker assay to detect circulating antigen in patients infected with Coccidioides.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

 Inclusion Criteria:                                                                  

  • Community acquired pneumonia: one of the following:
    • CXR or CT evidence of pulmonary infiltrate;
    • Clinical impression as documented by physician or advanced practice provider.
  • Symptom duration not longer than 14 days.
  • Age ≥18 years.
  • Inpatient or Outpatient.

 Exclusion Criteria:

  • Known prior coccidioidal illness (prior to onset of current illness):
    • Known prior coccidioidal history;
    • Known prior positive coccidioidal skin test;
    • Known prior coccidioidal serology in past.        
  • Health-care associated pneumonia:
    • Hospitalization in an acute care hospital for ≥ 2 days within 90 days of current infection;
    • Residence in nursing home or long-term care facility;
    • Recent IV antibiotic therapy, chemotherapy or wound care ≤ 30 days prior to current infection, given for a pneumonia indication;
    • Attended a hemodialysis clinic within 30 days.
  • Active COVID-19 infection (i.e., positive PCR or antigen test in the previous 4 months for which symptoms had yet to resolve.  Persistent symptoms (fever, cough, headache, chest pain, shortness of breath) that are unresolved are grounds for exclusion.
  • No exclusions for underlying health problems other than the above. Patients with underlying immunosuppression will be enrolled only as a subset of total patients enrolled.  Acceptable underlying immunosuppression will be defined as the receipt of immunosuppressive medications (within ≤ 3 months) such as but not limited to systemic corticosteroids greater than or equal to an equivalent dose of prednisone 5 milligrams daily, calcineurin inhibitors (tacrolimus, etc.), mycophenolate mofetil, rapamycin, others.

Eligibility last updated 10/5/21. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Janis Blair, M.D.

Open for enrollment

Contact information:

Sonia Robertson

(480) 342-6677


More information


Publications are currently not available